

DAFTAR PUSTAKA

- Barbesino, G., Tomer, Y., 2013. Clinical review: Clinical utility of TSH receptor antibodies. *J. Clin. Endocrinol. Metab.* 98, 2247–2255.
- Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. *Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.* *J Ophthalmol.* 2015;2015:249125. doi: 10.1155/2015/249125. Epub 2015 Aug 17. PMID: 26351570; PMCID: PMC4553342
- Bartalena, Luigi, Lelio Baldeschi, Kostas Boboridis, Anja Eckstein, George J. Kahaly, Claudio Marcocci, *et al.* 2016. “The 2016 European Thyroid Association/European Group on *Graves' Orbitopathy* Guidelines for the Management of *Graves' Orbitopathy*.” *European Thyroid Journal* 5(1):9–26. doi: 10.1159/000443828.
- Bartalena, Luigi, and Georg Hennemann. 2014. *Graves' Disease: Complications*
- Bean NG, Fajar SP, Thyroid stimulating hormone (TSH) autoregulation reduces variation in the TSH response to thyroid hormones. *Temperature (Austin)*. 2018 Oct 8;5(4):380-389. doi: 10.1080/23328940.2018.1513110. PMID: 30574530; PMCID: PMC6298488.
- Benvenega S, Tuccari G, Ieni A, Vita R. Thyroid gland: Anatomy and physiology. Ed: *Encyclopedia of Endocrine Diseases*. 2018. p. 1–5.
- Binboga S, Gemici E, Binboga E. Thyroid Anatomy. Ed: *Knowledges on Thyroid Cancer*. 2019. p. 1–6.
- Boyanov M, Bakalov D, Sheinkova G. Level of Thyroid Autoantibodies in Patients with *Graves' Disease* and *Graves' Ophthalmopathy*. *Society of Endocrinology and Metabolism of Turkey*. 2010;14: 50-53
- Braun D, Schweizer U. Thyroid Hormon Transport and Transporters. *Vitam Horm.* 2018;106:19–44.
- Brent GA. Mechanisms of thyroid hormone action. *J Clin Invest.* 2012;122(9):3035–43.
- Brix K, Szumska J, Szumska J, Weber J, Qatato M, Venugopalan V, *et al.* Auto-Regulation of the Thyroid Gland beyond Classical Pathways. *Exp Clin Endocrinol Diabetes.* 2020;128(6–7):437–45.
- Burch HB, Cooper DS. Management of *Graves' disease* a review. *JAMA - J Am Med Assoc.* 2015;314(23):2544–54.
- Campi, I., Vannucchi, G., Salvi, M., 2016. THERAPY OF ENDOCRINE DISEASE: Endocrine dilemma: management of *Graves' orbitopathy*. *Eur. J. Endocrinol.* 175, R117-133.
- Chistiakov DA. Thyroid-stimulating hormone receptor and its role in *Graves' disease*. *Mol Genet Metab.* 2003 Dec;80(4):377-88. doi: 10.1016/j.ymgme.2003.09.001. PMID: 14654350.
- Detweiler K, Elfenbein DM, Mayers D. Evaluation of Thyroid Nodules. *Surgical Clinics of North America*. 2019. p. 1–14.

- Dolman, P.J., Rootman, J., 2006. VISA Classification for *Graves'* orbitopathy. *Ophthalm. Plast. Reconstr. Surg.* 22, 319–324.
- Eckstein, A.K., Plicht, M., Lax, H., Neuhäuser, M., Mann, K., Lederbogen, S., *et al*, 2006. Thyrotropin receptor autoantibodies are independent risk factors for *Graves'* ophthalmopathy and help to predict severity and outcome of the disease. *J. Clin. Endocrinol. Metab.* 91, 3464–3470.
- Fajar, JK; Hidayah CI; Zaini, LM; Zufry, Hendra; Jamhur: Korelasi Derajat *Graves'* Ophthalmopathy dengan Durasi Menderita Hipertiroid. *Cermin Dunia Kedokteran*. 2015;42(5) 327-330.
- FitzPatrick AM. Is Estrogen a Missing Culprit in Thyroid Eye Disease? Sex Steroid Hormon Homeostasis Is Key to Other Fibrogenic Autoimmune Diseases - Why Not This One? *Front Immunol.* 2022 Jun 17;13:898138. doi: 10.3389/fimmu.2022.898138. PMID: 35784325; PMCID: PMC9248759.
- Floridi C, Cellina M, Buccimazza G, Arrichiello A, Sacrini A, Arrigoni F, *et al*. Ultrasound imaging classifications of thyroid nodules for malignancy risk stratification and clinical management: State of the art. *Gland Surgery*. 2019;8:234–42
- Gerding, M.N., van der Meer, J.W., Broenink, M., Bakker, O., Wiersinga, W.M., Prummel, M.F., 2000a. Association of thyrotrophin receptor antibodies with the clinical features of *Graves'* ophthalmopathy. *Clin. Endocrinol. (Oxf.)* 52, 267–271.
- Gontarz-Nowak K, Szychlińska M, Matuszewski W, Stefanowicz-Rutkowska M, Bandurska-Stankiewicz E. Current knowledge on *Graves'* orbitopathy. *J Clin Med*. 2021;10(1):1–23.
- Higgins, V., Patel, K., Kulasingam, V., Beriault, D.R., Rutledge, A.C., Selvaratnam, R., 2020. Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays. *Clin. Biochem.* 86, 56–60.
- Hoermann R, Midgley JEM, Larisch R, Dietrich JW. Recent advances in thyroid hormone regulation: Toward a new paradigm for optimal diagnosis and treatment. *Front Endocrinol (Lausanne)*. 2017;8(DEC):1–8.
- Jarusaitiene, D., Verkauskiene, R., Jasinskas, V., Jankauskiene, J., 2016. Predictive Factors of Development of *Graves'* Ophthalmopathy for Patients with Juvenile *Graves'* Disease. *Int. J. Endocrinol.*
- Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of *Graves'* hyperthyroidism. *European Thyroid Journal*. 2018;7(4):167–86.
- Kawashima A, Tanigawa K, Akama T, Yoshihara A, Ishii N, Suzuki K. Innate immune activation and thyroid autoimmunity. *J Clin Endocrinol Metab*. 2011;96(12):3661–71.
- Khan MS. *Graves'* Disease: Patophysiology, Genetics and Management. InTech Open. 2016;1:1–16.
- Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, Ebeling PR. Risk Factors for *Graves'* Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. *Journal Clinical Endocrinology Metabolic*. 2016 Jul;101(7):2711-20. doi: 10.1210/jc.2015-4294. Epub

2016 Apr 7. PMID: 27055083.

Kotwal, A., Stan, M., 2018. Thyrotropin Receptor Antibodies-An Overview. *Ophthalm. Plast. Reconstr. Surg.* 34, S20–S27.

Kummer, S., Hermsen, D., Distelmaier, F., 2016. Biotin Treatment Mimicking Graves' Disease. *N. Engl. J. Med.* 375, 704–706.

Lazarus JH. Epidemiology of *Graves'* orbitopathy (GO) and relationship with thyroid disease. *Best Pract Res Clin Endocrinol Metab.* 2012 Jun;26(3):273-9. doi: 10.1016/j.beem.2011.10.005. PMID: 22632364.

Lee ACH, Kahaly GJ. Novel Approaches for Immunosuppression in *Graves'* Hyperthyroidism and Associated Orbitopathy. *Eur Thyroid J.* 2020 Dec;9(Suppl 1):17-30. doi: 10.1159/000508789. Epub 2020 Aug 10. PMID: 33511082; PMCID: PMC7802437.

Lin MC, Hsu FM, Bee YS, Ger LP. Age influences the severity of *Graves'* ophthalmopathy. *Kaohsiung J Med Sci.* 2008 Jun;24(6):283-8. doi: 10.1016/S1607-551X(08)70154-2. PMID: 18635413.

Lote, Y. L. (2017). Hubungan Kadar Selenium Serum dengan Penyakit *Graves'* dan Oftalmopati *Graves'*. Universitas Hasanuddin Makassar.

McLachlan, S.M., Rapoport, B., 2013. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. *Thyroid Off. J. Am. Thyroid Assoc.* 23, 14–24.

Mukasa K, Yoshimura Noh J, Kouzaki A, Ohye H, Kunii Y, Watanabe N, *et al.*, TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of *Graves'* ophthalmopathy in untreated Japanese *Graves'* disease patients. *Endocr J.* 2016;63(2):151-7. doi: 10.1507/endocrj.EJ15-0137. Epub 2015 Nov 18. PMID: 26581710.

Nabi, Tauseef, and Rafiq, Nadeema. 2020. "Factors Associated with Severity of Orbitopathy in Patients with *Graves'* Disease." *Taiwan Journal of Ophthalmology* 10(3). doi: 10.4103/tjo.tjo_10_20

Nusanti, S. (2021). Evaluasi 97 Pasien Oftalmopati *Graves'* Selama 3 Tahun Menggunakan Algoritma Eugogo dan Konsensus Nasional. *Ophthalmologica Indonesiana*, 47(2), 66-72.

Paravina M., Stanojevic M., Velickovic M., Petrovic S. Milosavljevic M., 2012, A Triad of Exophtalmos, Pretibial Myxedema and Acropachy in A Patient with *Graves'* Disease. *Serbian Journal of Dermatology and Venereology*, 4 (2): 85- 91

Petrovic MJ, Sarenac T., Sreekovic S., Petrovic M., Vulovic D Janicjevic K., 2012. Evaluation of the Patients with *Graves'* Ophthalmopathy after Corticosteroids Treatment. *Vojnosanitetski Pregled*, 69 (3): 249-52

Pinto W, Romaldini JH, Perini N, Santos RB, Villagelin D. The change in the clinical presentation of *Graves'* disease: A 30 years retrospective survey in an academic Brazilian tertiary center. *Arch Endocrinol Metab.* 2020;64(5):514–20.

Pouso-Diz JM, Abalo-Lojo JM, Gonzalez F. Thyroid eye disease: current and potential medical management. *Int Ophthalmol.* 2020 Apr;40(4):1035-1048. doi: 10.1007/s10792-019-01258-7. Epub 2020 Jan 9. PMID: 31919775.

- Prabhakar BS, Bahn RS, Smith TJ. Current Perspective on the Pathogenesis of *Graves' Disease* and Ophthalmopathy. *Endocr Rev.* 2003;24(6):802–35.
- Pritchard, Jane, Rui Han, Noah Horst, William W. Cruikshank, and Terry J. Smith. 2003. "Immunoglobulin Activation of T Cell Chemoattractant Expression in Fibroblasts from Patients with *Graves' Disease* Is Mediated Through the Insulin-Like Growth Factor I Receptor Pathway." *The Journal of Immunology* 170(12):6348–54. doi: 10.4049/jimmunol.170.12.6348
- Putra. 2021. Hubungan Kadar Thyroid Stimulating Hormone Receptor Antibody (TRAb) Terhadap Aktivitas dan Derajat Keparahan Klinis Oftalmopati Graves Di RSUP Dr. Sardjito Yogyakarta (Doctoral dissertation, Universitas Gadjah Mada).
- Ross, D.S., Burch, H.B., Cooper, D.S., Greenlee, M.C., Laurberg, P., Maia, A.L., et al 2016. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid Off. J. Am. Thyroid Assoc.* 26, 1343–1421.
- Şahlı E, Gündüz K. Thyroid-associated Ophthalmopathy. *Turk J Ophthalmol.* 2017 Apr;47(2):94-105. doi: 10.4274/tjo.80688. Epub 2017 Apr 1. PMID: 28405484; PMCID: PMC5384127.
- Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, et al. Serum concentrations of proinflammatory cytokines in *Graves' disease*: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. *European Journal Endocrinology.* 2000 Aug;143(2):197-202. doi: 10.1530/eje.0.1430197. PMID: 10913938.
- Savitri A.D, Sutjahjo A, Soelistijo S.A, Baskoro A: Comparison of Thyroid Stimulating Hormone Receptor Antibody (TRAb) In *Graves' Disease* Patients with and Without Ophthalmopathy. The New Armenian Medical Journal Vol.13 (2019), No 4, p. Address for Correspondence: 39-46
- Schott, M., Hermesen, D., Broecker-Preuss, M., Casati, M., Mas, J.C., Eckstein, A., et al Stock, W., Noh, J.Y., Scherbaum, W.A., Mann, K., 2009. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of *Graves' disease* (GD): an international multicentre trial. *Clin. Endocrinol. (Oxf.)* 71, 566–573.
- Seethalakshmi, MSI and Rebecca MB. Immunopathogenesis of *Graves' ophthalmopathy*: the role of the TSH receptor. HHS Public Access. 2013;26(3):2819.
- Shyamasunder AH, Abraham P. Measuring TSH receptor antibody to influence treatment choices in *Graves' disease*. *Clin Endocrinol (Oxf.)*. 2017 May;86(5):652-657. doi: 10.1111/cen.13327. PMID: 28295509.
- Srikandi PR. Hipertiroidisme *Graves' Disease*: Case Report. J Kedokt RAFLESIA. 2020;6(1):30–5.
- Subekti, I; Boedisantoso, A; Moeloek, NDF; Waspadji, S; Mansyur, M: Association of TSH Receptor Antibody, Thyroid Stimulating Antibody, and Thyroid Blocking Antibody with Clinical Activity Score and Degree of Severity of *Graves' Ophthalmopathy*. Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine. 2012. Vol 44 Number 2.
- Sugimoto K, Mori K. Thyroid-Stimulating Hormone Regulation and Transcription

- in Hypothyroidism. Hypothyroidism - Influent Treat. 2012;(October).
- Tabasum A, Khan I, Taylor P, Das G, Okosieme OE. Thyroid antibody-negative euthyroid Graves' ophthalmopathy. *Endocrinol Diabetes Metab Case Report*. 2016;2016:160008. doi: 10.1530/EDM-16-0008. Epub 2016 Jun 2. PMID: 27284451; PMCID: PMC4898069.
- Ulla Feldt-Rasmussen ÅKR. Thyroid Hormon Transport and Actions. *Dis Thyroid Child Adolesc*. 2015;11:80–103.
- Visser WE, Friesema ECH, Visser TJ. Minireview: Thyroid hormone transporters: The knowns and the unknowns. *Mol Endocrinol*. 2011;25(1):1–14.
- Wang Y. & Smith TJ., 2014. Current Concepts in the Molecular Pathogenesis of Thyroid Associated Ophthalmopathy. *Investigative Ophthalmology & Visual Science*, 55: 1735- 48
- Werner SC. Modification of the classification of the eye changes of Graves' disease. *Am J Ophthalmol*. 1977 May;83(5):725-7. doi: 10.1016/0002-9394(77)90140-4. PMID: 577380.
- Wiersinga WM. Graves' Disease: Can It Be Cured?. *Endocrinol Metab (Seoul)*. 2019 Mar;34(1):29-38. doi: 10.3803/EnM.2019.34.1.29. PMID: 30912336; PMCID: PMC6435849.
- Zimmermann, Michael B., and Kristien Boelaert. 2015. "Iodine Deficiency and Thyroid Disorders." *The Lancet Diabetes and Endocrinology* 3(4):286–95. doi: 10.1016/S2213-8587(14)70225-6